arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

SOLIGENIX, INC.

SNGX
$0.33 ▼ -0.03 (-7.28%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

SOLIGENIX, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -214.0% →
FCF / Share $-1.98 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$119.37K
↓ -85.8% —
Net Income Profit after all expenses
$-11.08M
↓ -34.0% —
Operating Margin Operating profit as % of sales
-227.7%
↓ -31.7% —
FCF / Share Free cash flow per share
$-1.98
↑ +60.9% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Financial Health ↓
8
Cash Quality →
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 17 years · 67 quarters